Breaking Finance News

Oppenheimer issued a report on Seres Therapeutics (LON:MCRB), stepping up its target to 19.00GBX today

Having a price of 10.87GBX, Seres Therapeutics (LON:MCRB) traded 0.00% even on the day. The last closing price is up 0.00% from the 200-day moving average, compared to the S&P 500 Index which has increased 0.03% over the date range. Seres Therapeutics has recorded a 50-day moving average of 0.00GBX and a 200-day moving average of 0.00GBX. 0 shares of MCRB traded, down from an average trading volume of 0

Seres Therapeutics (LON:MCRB) had its target bumped up to 19.00GBX by Oppenheimer in an issued report announced 10/13/2017. The upped price target implies a potential upside of 0.75% based on the company's last closing price.

On 8/04/2017, H.C. Wainwright released a statement for Seres Therapeutics (LON:MCRB) upped the target price from 15.00GBX to 19.00GBX that suggested an upside of 0.47%.

Recent Performance Chart

Seres Therapeutics (LON:MCRB)

Seres Therapeutics has a one year low of 0.00GBX and a one year high of 0.00GBX Seres Therapeutics’s market capitalization is presently 0 GBX.

More About Seres Therapeutics (LON:MCRB)

MCB Finance Group plc is a United Kingdom based online provider of short and medium-term loans to customers in Finland, Estonia, Latvia, Lithuania and Australia. The Company offers credit solutions and loans are available through Credit24 brand to retail customers in Finland, Estonia, Latvia, Lithuania and Australia, and through selected distribution partners. Credit24 offers non-standard loans in the market. The Company's products include unsecured loans up to approximately 2,000 Euros to qualifying customers, with maturities up to two years. Applications are made through the Company's Credit24-branded websites in each country and the loans are offered online and also through certain distribution partners.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *